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ruthenium(II)-arene complex [Ru(h6-p-cymene)-
Cl2(pta)] (RAPTA-C) in human ovarian and
colorectal carcinomas†
Andrea Weiss,ab Robert H. Berndsen,b Maxime Dubois,c Cristina Mu¨ller,c
Roger Schibli,cd Arjan W. Griﬃoen,b Paul J. Dyson*a and Patrycja Nowak-Sliwinska*a
Based on the clinical success of platinum-based anti-cancer drugs such as cisplatin, carboplatin and
oxaliplatin, a variety of other metal-based anti-cancer compounds are being investigated. In particular, a
number of ruthenium-based compounds have been identiﬁed which exhibit unique biochemical
properties and reduced toxicity proﬁles compared to the clinically used platinum-based drugs. We have
developed a series of organometallic ruthenium(II)-arene complexes that were shown to exert anti-
metastatic activity with relatively minor activity on primary tumor growth. Here, we show that the
prototype compound, [Ru(h6-p-cymene)Cl2(pta)], where pta ¼ 1,3,5-triaza-7-phosphaadamantane
(RAPTA-C), reduces the growth of primary tumors in preclinical models for ovarian and colorectal
carcinomas. When administered daily at relatively low doses (0.2 mg kg1), RAPTA-C was shown to
signiﬁcantly reduce the growth of the A2780 ovarian carcinoma transplanted onto the chicken
chorioallantoic membrane model. Similar activity was observed in LS174T colorectal carcinoma in
athymic mice, albeit at a higher dose. In both models, a clear inhibition of microvessel density was
observed, conﬁrming the previously discovered anti-angiogenic mechanism of RAPTA-C. Biodistribution
studies with radiolabeled (103Ru) RAPTA-C indicate that the compound is rapidly cleared from the organs
and the bloodstream through excretion by the kidneys. As such, RAPTA-C is a promising compound for
translation to clinical evaluation.Introduction
Cisplatin, carboplatin and oxaliplatin are widely used in the
clinical treatment of a broad spectrum of cancers.1 Despite the
success of these platinum-based drugs, their use is limited due
to signicant toxicity and both intrinsic and acquired drug
resistance.2 In light of these limitations, a large focus in current
research has been directed towards the development of
compounds that are based on metals other than platinum.2,3 In
recent years, the prominence of ruthenium-based complexes
has signicantly grown as they have been shown to possess anti-
metastatic properties and overcome both of these maining, Swiss Federal Institute of Technology
atrycja.Nowak-Sliwinska@ep.ch; Paul.
61 693 9780; Tel: +41 21 693 5169; +41
edical Oncology, VU University Medical
TH-PSI-USZ, Villigen-PSI, Switzerland
ciences, ETH Zurich, Zurich, Switzerland
tion (ESI) available. See DOI:limitations of platinum-based drugs in a number of animal
models.4,5 Two ruthenium(III)-based compounds (Chart 1),
namely KP1019 (indazolium trans-[tetrachlorobis(1H-indazole)-
ruthenate(III)]) and NAMI-A (imidazolium trans-[tetra-
chloro(dimethylsulfoxide)(1H-imidazole)ruthenate(III)]), have
undergone phase I clinical evaluation.
Ruthenium(III) complexes, however, are prone to ligand
exchange reactions in aqueous media/physiological buﬀer
which hamper, to some extent, the rational design of such newChart 1 Structures of KP1019 (A) and NAMI-A (B).
This journal is © The Royal Society of Chemistry 2014
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View Article Onlinecompounds with relevant medicinal properties. For this reason,
ruthenium(II)-arene compounds have attracted considerable
attention in recent years following encouraging in vivo data on
two prototypical compounds (Chart 2), [Ru(h6-p-cymene)Cl(en)],
where en ¼ ethylenediamine (termed RAED-C)6 and [Ru(h6-
p-cymene)Cl2(pta)], where pta ¼ 1,3,5-triaza-7-phosphaada-
mantane (termed RAPTA-C).7 RAED-C was shown to have a
moderate eﬀect on reducing the growth of primary tumors
whereas RAPTA-C has shown moderate eﬀects on solid tumor
metastases. Recently, these diﬀerences have been tentatively
attributed to diﬀerences in the preferential binding site of each
molecule to chromatin, with RAED-C binding to DNA sites and
RAPTA-C to the histone core.8
The mechanisms by which ruthenium-based drugs exert
their anticancer eﬀects remain to be fully elucidated although,
as mentioned above, chromatin binding appears to be an
important mechanism. It has been proposed for ruthenium(III)
complexes that their reduced toxicity to normal tissue may be
attributed to the so-called “activation by reduction” mecha-
nism, i.e. ruthenium(III) complexes act as prodrugs that can be
reduced to active ruthenium(II) species in the hypoxic micro-
environment of a tumor. Similar to KP1019 and NAMI-A, which
are both based on a ruthenium(III) ion, the ruthenium(II)
complex RAPTA-C also appears to be well tolerated in vivo
showing considerably reduced side-eﬀects compared to plat-
inum-based drugs (as judged by the high doses that may be
tolerated by animals).
RAPTA-C was recently shown to also exert a strong anti-
angiogenic eﬀect,9 similar to that of sorafenib, a clinically used
anti-angiogenic small molecule drug.10 Moreover, there are
similarities shared by RAPTA-C and NAMI-A, both of which
show limited direct cytotoxic eﬀects on cancer cells in vitro
while exhibiting anti-metastatic behaviour in vivo. NAMI-A also
has an anti-angiogenic component to its mechanism as
demonstrated by its ability to induce apoptosis in a spontane-
ously transformed human endothelial cell line (ECV304)
through the inhibition of MEK/ERK signalling.11
RAPTA-C presents particular interest when viewed as an anti-
angiogenic agent, as it has been shown to reduce the growth of
lung metastases in CBA mice bearing the MCa breast carci-
noma,12 while many clinically used VEGF-targeted therapies
have been shown to induce pro-metastatic phenotypes in
treated tumors, such as the VEGF targeted tyrosine kinase
inhibitor sunitinib.13 Consequently, RAPTA-C is an attractive
compound for further pre-clinical development. Therefore, we
decided to evaluate the eﬀects of RAPTA-C in more detail on
primary tumors of human carcinomas. The results presentedChart 2 Structures of RAED-C (A) and RAPTA-C (B).
This journal is © The Royal Society of Chemistry 2014here demonstrate that RAPTA-C possesses anticancer activity, in
conjunction with an intrinsic anti-angiogenic mechanism on
primary tumors.
Results and discussion
The eﬀect of RAPTA-C on tumor growth inhibition was inves-
tigated in a human A2780 ovarian carcinoma implanted on the
chicken chorioallantoic membrane (CAM) model. A2780 cells
were inoculated on embryo development day (EDD) 7 and
monitored for 11 days. Established and vascularized tumors
were detected 3 days post implantation (EDD 10). Treatment
with RAPTA-C was performed by i.v. injections for ve consec-
utive days (Fig. 1A). Tumors grew to an average size of approx-
imately 160 mm3 by EDD 18 when le untreated (Fig. 1C).
Tumor growth was eﬃciently inhibited following treatment
with RAPTA-C and on the nal experiment day, the growth of
tumors was inhibited by about 75% (**p ¼ 0.0007) at a dose of
0.2 mg kg1 per day (Fig. 1B). An inhibition of ca. 45% was
observed at a dose of 0.05 and 0.02 mg per kg per day, however,
neither were statistically signicant. It is noteworthy that READ-
C (10 mg kg1, i.p.) tested on tumor derived from the same cell
line in athymic mice showed tumor growth inhibition of about
50% at 10-fold higher dose as compared to that used in our
study, which resulted in the inhibition of tumor growth by
75%.6 The eﬀect of RAPTA-C was, in fact, comparable to that of
cisplatin in this study.6
The eﬀect of RAPTA-C treatment on the process of angio-
genesis was assessed by measuring the vessel density using
immunohistochemical staining of the CAM tissue sections with
the endothelial cell marker CD31.14 Staining of tumor sections
for the nuclear proliferation marker Ki-67 was performed to
determine intra-tumor cell viability.15 Tumors were resected on
the last day of the experiment (EDD 18). The control samples
contained viable tumor tissue with many blood vessels whereas
the treated tissues contained large areas of non-proliferating
tumor cells (Fig. 1D and F, **p ¼ 0.0099). Additionally, quan-
tication of the microvessel density in the sparse viable tissue
remaining revealed signicantly reduced microvessel density
(0.2 mg kg1 per day), as compared to the control tumors
(Fig. 1E). These results conrm the in vivo antitumor activity of
RAPTA-C was achieved in parallel to an anti-angiogenic eﬀect.
RAPTA-C was also evaluated in Swiss athymic mice inocu-
lated on the right ank with human LS174T colorectal adeno-
carcinoma cells. When tumor size reached approximately 5–6
mm in diameter (day 5 aer inoculation), the mice were
randomized into groups and treated once daily with RAPTA-C
(i.p. 10, 40 or 100 mg kg1) for 11 days or with PBS only (con-
taining 0.9% DMSO) as a control. Spectroscopic characteriza-
tion of RAPTA-C in DMSO solutions with or without albumin is
presented in Fig. S1 (ESI†), showing that the compound is stable
under the treatment conditions, as expected from previous
studies.16 Tumor growth was monitored during treatment and,
aer this period, mice were sacriced and tumors were resec-
ted. Tumor growth of RAPTA-C treated tumors (i.p. 100 mg kg1
per day) was inhibited (**p ¼ 0.008) by approximately 50%
compared to the control group (Fig. 2A) on the last experimentChem. Sci., 2014, 5, 4742–4748 | 4743
Fig. 1 Inhibition of A2780 tumor growth in the CAM model by RAPTA-C. (A) Treatment protocol: RAPTA-C was administered i.v. on treatment
days 1–5 (corresponding to EDD 11–15) and tumors were excised on the last day of the experiment. (B) Growth curve of A2780 tumors grafted on
the CAM showing tumor volume with respect to treatment day. (C) Images show representative tumors from the vehicle treated (CTRL) and
RAPTA-C (0.2 mg kg1) treated CAMs. (D) Representative images of the immunohistochemical staining of the endothelial cell marker CD31 (in
brown) showing reduced microvessel density per mm2 in tumors treated with RAPTA-C normalized to the tumor surface area and provided as a
% of the control (E) and Ki-67 positive nuclei (in blue) (D) and quantiﬁcation of the percentage of the tumor surface area staining positive for Ki-67
(as a % of CTRL) (F). Black bar in the right image of (D) represents 500 mm and is valid for both images. Error bars represent standard error of the
mean, SEM; N ¼ 5 in all treatment groups; N > 5 CTRL group; **p < 0.01.
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View Article Onlineday. Lower doses (10 and 40 mg kg1 per day) did not lead to
signicant tumor growth inhibition. We did not observe toxicity
during the course of treatment. The average body weight of
animals in the treatment groups did not change signicantly
over the course of treatment (Fig. 2B).
KP1019 has been evaluated in various colorectal tumor
models and was found to have a strong activity in a chemo-
resistant colon carcinoma model (MAC15A) and was subse-
quently tested in an autochthonous colorectal tumor model in
rats, which more accurately reects both the histological
appearance and malignant progression of human disease.17 In
this model, KP1019 was highly eﬀective, resulting in approxi-
mately 90% tumor growth inhibition. It was more eﬀective that
cisplatin, which was completely ineﬀective, and 5-uorouracil
treatment. 5-Fluorouracil therapy, which is a standard treat-
ment for colorectal carcinoma and is the most eﬀective single
agent therapy, inhibited tumor growth by 60% as compared to
the control tumors.18,19 Treatment of CBA mice with MCa
mammary carcinoma with KP1019 administered at 40 mg per
kg per day from day 6 to day 11 post tumor implantation (6 daily4744 | Chem. Sci., 2014, 5, 4742–4748administrations) resulted in a reduction of primary tumor
weight by 67% relative to the tumor mass in the control
animals.20
Treated tumor tissue sections were stained for endothelial
cells (with CD31 staining in brown) and smooth muscle actin
(with anti-SMA in blue), indicating the presence of mature
blood vessels (Fig. 2C and D). Tumor size measurements
appeared to be an underestimation of the RAPTA-C activity, as
treated tumors showed large areas of necrosis. In addition,
around the remaining blood vessels small patches of Ki-67
negative tumor cells were observed, indicating that that tumor
cells are in a quiescent state (Fig. S2, ESI†). Quiescence
describes reversible growth or proliferation arrest and is
considered to represent a state induced by diverse anti-mito-
genic signals leading to cell division arrest.21 Interestingly,
assessment of microvessel density revealed a signicant
decrease in the number of blood vessels in treated tumors
(Fig. 2C, for 100 mg kg1 per day), indicating a strong anti-
angiogenic eﬀect. SMA staining revealed that RAPTA-C treat-
ment resulted in normalized, more mature blood vessels thatThis journal is © The Royal Society of Chemistry 2014
Fig. 2 RAPTA-C induced inhibition of human LS174T colorectal carcinoma tumor growth in athymicmice. (A) RAPTA-C dose dependent growth
curves of LS174T tumors. (B) Relative weight change of treated mice during the experiment. The average weight of mice in the RAPTA-C 100 mg
kg1 treatment group was not signiﬁcantly diﬀerent between treatment days 1 and 11 (p ¼ 0.06). (C) Representative images of CD31 positive
immunohistochemical sections of CTRL and RAPTA-C (100 mg kg1) treated tumors on the last day of experiment and microvessel density
quantiﬁcation, expressed as the number of vessels per mm2 (**p¼ 9.6 107). Magniﬁcation 4, bar in the right image represents 500 mm and is
valid for both images. (D) Representative images of SMA and CD31 positive immunohistochemical sections of CTRL and RAPTA-C (100 mg kg1)
treated tumors on the last day of experiment and their quantiﬁcation (*p ¼ 0.0166). Magniﬁcation 20, bar in the right image represent 100 mm
and is valid for both images. Error bars represent SEM; N ¼ 3–9 mice per group. *p < 0.05, **p < 0.01.
Fig. 3 RAPTA-C biodistribution after injection in Balb/c mice. Mice
were injected i.p. with 103Ru-RAPTA-C (1.9 MBq per mouse) and were
sacriﬁced 2 hours post injection and their organs were resected. The
data are presented as % injected dose per gram of tissue (% ID per g).
Indicated values are means, error bars represent SEM.
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View Article Onlinewere covered by pericytes. While control tumors were charac-
terized by numerous, newly generated and immature blood
vessels lacking pericytes (CD31+/SMA), we noticed that treat-
ment with RAPTA-C resulted in the disappearance of this newly
formed angiogenic vasculature and led to an increased number
of mature vessels covered by pericytes (CD31+/SMA+, Fig. 2D).
This observation further conrms the angiostatic activity of
RAPTA-C.
The low toxicity of RAPTA-C when applied at quite high doses
is remarkable and therefore the accumulation of RAPTA-C was
studied in order to rationalize, at least in part, the absence of
toxicity. The biodistribution of radioactively labelled 103Ru-
RAPTA-C in healthy Balb/c mice was determined (Fig. 3). The
procedure used to prepare 103Ru-RAPTA-C is provided in the
Experimental section. Two hours aer injection, it was found
that the level of ruthenium in the urine was ca. 28-fold higher
than in liver, spleen, lungs and heart, indicative of fast and
eﬃcient renal excretion. Ruthenium was not found to speci-
cally accumulate in any of the tested organs. The slightly higher
levels in the kidneys (approx. 2-fold) and intestines (approx.
3-fold) may be expected only 2 hours aer injection. These data
parallel a previous pharmacokinetic study in which RAPTA-C
was injected i.p. in healthy Swiss CD-1 mice.7 In this previous
study, the content of ruthenium in the blood, plasma, and in
selected organs (liver, kidney, spleen, and lung) was quantied
by atomic absorption spectroscopy. A half-life (T1/2) of about 12This journal is © The Royal Society of Chemistry 2014hours was estimated that varied slightly depending on the dose
and administration schedule. Two hours aer RAPTA-C
administration, the concentration of RAPTA-C in kidneys was 2-
fold higher than in the spleen, while the majority of ruthenium
was eliminated in urine within 1 hour of administration. The
previous and current data show that the rate of clearance ofChem. Sci., 2014, 5, 4742–4748 | 4745
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View Article OnlineRAPTA-C is faster than that of NAMI-A.22 A 106Ru analogue of
RAED-C revealed that the highest levels of the compound were
associated with the liver and kidney.23
Experimental
General chemicals
Ruthenium(III) chloride hydrate (35–40% Ru) was obtained from
Merck and 1,3,5-triaza-7-phosphaadamantane (pta) 97% and
(R)-()-a-phellandrene $95% (sum of enantiomers) were
obtained from Sigma-Aldrich. Purication of the 103Ru-RAPTA-
C was performed using Silica gel 60 from Fluka.
103RuCl3$3H2O production
Neutron activation of natural RuCl3$3H2O gave the
103RuCl3$3H2O. Irradiations were performed with the spallation
neutron source SINQ at the PSI. Irradiation of natural ruthe-
nium with a neutron ux of 1014 n cm2 s1 gave the following
radionucleides: 97Ru (T1/2 ¼ 2.9 days), 103Ru (T1/2 ¼ 39.3 days)
and 105Ru (T1/2 ¼ 4.44 h). The thermal cross section of
102Ru (s ¼ 1.27 barn) and the relative long half-life of 103Ru
compared to the other radionucleides produced allowed for the
production of 103Ru with high radionuclidic purity with 97Ru
or 105Ru activities undetectable aer 1 week of decay
(Fig. S3, ESI†). Neutron irradiation of the chlorides gave negli-
gible 36Cl and 38Cl activity.
Example: 15 mg natural ruthenium (39.9 mg RuCl3$3H2O)
were irradiated for 16.2 days with the 1014 n cm2 s1 ux giving
a 103Ru activity of 109.8 MBq from the 124.7 MBq expected.
103Ru activity was calculated according to the equation given in
the ESI.† The radiosynthesis of 103Ru-RAPTA-C was monitored
with a Cyclone phosphor imager (Perkin-Elmer).
103Ru-RAPTA-C radiosynthesis
103RuCI3$3H2O (13.6 mg, 0.05 mmol, 36.21 MBq) was sus-
pended in ethanol (6 ml) and underwent reux for 3 h to obtain
a dark green solution. (R)-()-a-Phellandrene (0.31 mmol) was
added to the reaction mixture and the reaction was stirred
under reux for 6 h. The reaction was cooled to room temper-
ature and diethyl ether (3 ml) was added to precipitate the [(p-
cymene)103RuCl2]2 dimer. The dimer was washed repeatedly
with diethyl ether to remove unreacted (R)-()-a-phellandrene.
The supernatant was removed with a ow of nitrogen and
replaced with dichloromethane (6 ml) and pta (8 mg, 0.05
mmol) was added to the solution. The reaction was stirred for 4Chart 3 Radio synthesis of 103Ru-RAPTA-C.
4746 | Chem. Sci., 2014, 5, 4742–4748h at room temperature. Purication using column chromatog-
raphy (Silica gel 60) with a methanol–dichloromethane 1 : 30
eluent gave the pure 103Ru-RAPTA-C (60.5%, 21.9 MBq). HPLC:
8.27 min at 342 nm; ESI-MS: 486m/z [Ru(h6-p-cymene)Cl2(pta) +
Na]+ (calc. 486.358), 464 m/z [Ru(h6-p-cymene)Cl2(pta) + H]
+
(calc. 464.376), 428 m/z [Ru(h6-p-cymene)Cl(pta)]+ (calc.
427.918), see Chart 3.Cell culture, preparation and implantation on the CAMmodel
A2780 human ovarian carcinoma cells (ECACC, Salisbury, UK)
were maintained in RPMI-1640 cell culture medium supple-
mented with GlutaMAX™ (Gibco, Carlsbad, USA), 10% heat-
inactivated bovine calf serum (Sigma-Aldrich, St. Louis, USA)
and 1% antibiotics (Sigma-Aldrich). Fertilized chicken eggs
were incubated in a hatching incubator (relative humidity 65%,
37 C), as previously described.24 A2780 cells (106) were prepared
in serum-free RPMI-1640 as a spheroid in a 25 ml hanging drop
and 3 h later were transplanted on the surface of the in ovo CAM
on EDD 825 (Fig. 1A). Vascularized three-dimensional tumors
were visible 3 days aer tumor cell implantation, on EDD 11,
when treatment was initiated. Tumors were treated daily by i.v.
injection of freshly prepared RAPTA-C into a main blood vessel
of the CAM. Aer preliminary experiments, we observed that the
most eﬃcient tumor growth inhibition was obtained with
RAPTA-C aer 5 intravenous injections, in the tested dose
range, on 5 consecutive days. Therefore, we used this treatment
schedule in the current study. RAPTA-C was dissolved in DMSO
to aﬀord a stock solution, which was subsequently diluted to the
desired concentrations in 0.9% NaCl. Controls were treated
with vehicle (DMSO in 0.9% NaCl). The concentration of drug
was administered each day for 5 consecutive days and doses
were calculated assuming an average embryo weight of 8.23
grams (i.e. the average embryo weight during the course of the 5
days of treatment). Tumors were monitors for a total of 11 days
aer cell implantation, at which time embryos were sacriced
and tumors were resected and xed in zinc-xative for addi-
tional analysis. N ¼ 5 in all treatment groups; N > 5 in the
control group.Cell implantation in athymic mice
Experiments in female 7-week old Swiss female athymic mice
purchased from Charles River (Orleans, France) were carried
out according to a protocol approved by the Committee for
Animal Experiments for the Canton Vaud, Switzerland (license
2736). Mice were injected subcutaneously in the right ank withThis journal is © The Royal Society of Chemistry 2014
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View Article Online0.5  106 LS174T cells (purchased from Cell Line Service GmbH
Eppelheim, Germany), previously cultured in DMEM supple-
mented with 10% heat-inactivated fetal calf serum and 1%
antibiotics). When tumors reached a size of 5–6 mm in diam-
eter, mice received 10, 40 or 100 mg kg1 of freshly prepared
RAPTA-C in 100 ml solution via i.p. injections. This treatment
was repeated daily for 11 consecutive days. Tumors dimensions
and body weight were measured daily. Tumor volumes (mm3)
were calculated as follows: volume ¼ (largest diameter in mm)
 (perpendicular diameter in mm)2  0.5. Mice were eutha-
nized when the CTRL tumor size reached 1000 mm3. N ¼ 9, 4, 6
and 3 mice for CTRL, 10 mg kg1, 40 mg kg1 and 100 mg kg1
treatment groups, respectively.Immunohistochemistry
On the last day of the experiment tumors were resected and
xed overnight in zinc xative solution. CAM and mice tumors
were stained as previously described.10,14 Briey, 5 mm sections
were blocked with 5% BSA in PBS followed by incubation with
primary antibodies against CD31 (rat anti-CD31; 1 : 200, clone
SZ31, Dianova, Hamburg, Germany). Secondary donkey anti-rat
biotinylated antibodies (1 : 200; Jackson, Suﬀolk, UK) were then
incubated, followed by Streptavidin-HRP (1 : 50; Dako,
Glostrup, Denmark), and visualized by 3,30-diaminobenzidine
(DAB), resulting in a brown-colored precipitate at the antigen
site. Subsequently, incubation with antibodies against smooth
muscle actin (SMA) (mouse anti-human SMA; 1 : 200, clone
MIB-1, Dako, Glostrup, Denmark) or Ki-67 (mouse anti-human
Ki-67; 1 : 200, clone 1A4, Dako, Gostrup, Denmark) was fol-
lowed by alkaline phosphatase conjugated polymer Mach 2
(Biocare Medical, Concord, USA) and visualized by Fast Blue BB/
Naphthol-AS-MX-Phosphate, resulting in a blue/purple-col-
oured precipitate.Biodistribution studies
The in vivo experiments were approved by the local veterinarian
department and conducted in accordance with the Swiss law of
animal protection. Three 6–8-week-old female, Balb/c mice were
purchased from Charles River Laboratories (Sulzfeld, Germany).
103Ru-RAPTA-C (1.9 MBq, 2.6 mmol, 100 mL per mouse) was
injected into a lateral tail vein. The animals were sacriced 2 h
aer drug administration. Selected tissues and organs were
collected, weighed, and counted for radioactivity using a g-
spectrometer running with InterWinner soware. The results
were listed as a percentage of the injected dose per gram of
tissue mass (% ID per g). Counts of a dened volume of the
original injection solution counted at the same time were used
as a reference.Statistical analysis
Values are given as mean values  standard error of the mean
(SEM). Data are represented as averages of independent exper-
iments. Statistical analysis was done using the two-way ANOVA
test and t-test using GraphPad Prism soware® (GraphPad
Soware Inc., CA). *p indicating p-values lower than 0.05 andThis journal is © The Royal Society of Chemistry 2014**p indicating p-values lower than 0.01 were considered statis-
tically signicant.Conclusions
Certain ruthenium-based compounds show promise as anti-
cancer agents with diﬀerent characteristics compared to clini-
cally applied platinum-based drugs.12,26–29 Our studies were
focused on an organometallic ruthenium(II)-arene complex, i.e.
RAPTA-C, that was shown to exhibit both anti-metastatic and
anti-angiogenic eﬀects.9,30 Herein, we describe the eﬀect of
RAPTA-C on the growth inhibition of primary tumors. In this
respect, RAPTA-C treatment was found to eﬃciently reduce the
growth of tumors by approx. 75% in one model, with the inhi-
bition of angiogenesis (determined by vessel density assess-
ment) being at least partly responsible for this action. An
eﬃcient and general induction of tumor cell death was observed
in the tumor tissue, with remaining viable tumor islands
completely negative for the proliferation marker Ki-67. These
results support the translational development of RAPTA-C into
clinical studies.Acknowledgements
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